Axogen posts 26% Q3 revenue jump, raises 2026 outlook to at least $290 million and completes BioCircuit acquisition

Axogen reported third‑quarter 2026 revenue of $75.8 million, a 26.2% year‑over‑year increase, and adjusted earnings of $0.21 per share. The company completed its acquisition of BioCircuit Technologies, funded by a $225 million public offering, and raised its full‑year 2026 revenue guidance to at least $290 million. Management highlighted strong growth in the breast reconstruction segment (over 50% YoY) and near‑universal payer coverage for its Avance nerve graft (about 96% of U.S. lives).

The raised revenue outlook signals higher top‑line growth than analysts had expected, which could support a higher valuation for AXGN (the company said the guidance reflects at least 29% growth). The BioCircuit acquisition adds the NerveTape product and is expected to be accretive to revenue and EBITDA margins (the company indicated it would contribute at least $7 million in 2026).

  • 1Q3 2026 revenue was $75.8 million, up 26.2% from the same quarter in 2025.
  • 2Adjusted earnings per share for Q3 2026 were $0.21.
  • 3Full‑year 2026 revenue guidance was raised to at least $290 million.
  • 4The company completed the acquisition of BioCircuit Technologies on October 1 2026, funded by a $225 million share offering, of which $200 million was used for the purchase.
  • 5Cash, cash equivalents, restricted cash and investments totaled $350.1 million as of September 30 2026.
  • 6Gross margin for Q3 2026 was 74.8%, down from 76.6% a year earlier.

Sources